Cocrystal Pharma, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed in the accompanying “Exhibit Index” are filed or incorporated by reference as part of this Form 10-Q.
EXHIBIT INDEX
| Exhibit · Incorporated by Reference · Filed or Furnished | |||||
|---|---|---|---|---|---|
| No. | Exhibit Description | Form | Date | Number | Herewith |
| 3.1 | Certificate of Incorporation, as amended | 10-Q | 8/16/21 | 3.1 | |
| 3.1(a) | Certificate of Amendment to Certificate of Incorporation – reverse stock split | 8-K | 10/3/22 | 3.1 | |
| 3.1(b) | Certificate of Amendment to Certificate of Incorporation – reduce number of authorized shares | 8-K | 6/28/24 | 3.1 | |
| 3.2 | Amended and Restated Bylaws | 8-K | 2/19/21 | 3.1 | |
| 3.2(a) | Amendment No. 1 to Amended and Restated Bylaws | 8-K | 6/18/25 | 3.1 | |
| 4.1 | Form of Investor Warrant | 8-K | 9/15/25 | 4.1 | |
| 4.2 | Form of Placement Agent Warrant | 8-K | 9/15/25 | 4.2 | |
| 10.1 | 2025 Equity Incentive Plan | 8-K | 4/8/25 | 10.1 | |
| 10.2 | Form of Securities Purchase Agreement | 8-K | 9/15/25 | 10.1 | |
| 10.3 | Form of Securities Purchase Agreement | 8-K | 10/30/25 | 10.1 | |
| 31.1 | Certification of Principal Executive Officer (302) | Filed | |||
| 31.2 | Certification of Principal Executive Officer (302) | Filed | |||
| 31.3 | Certification of Principal Financial Officer (302) | Filed | |||
| 32.1 | Certification of Principal Executive and Principal Financial Officer (906) | Furnished* | |||
| 101.INS | Inline XBRL Instance Document | Filed | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed | |||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | Filed | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | Filed | |||
- This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.
** Certain schedules and other attachments have been omitted. The Company undertakes to furnish the omitted schedules and attachments to the Securities and Exchange Commission upon request.
Copies of this report (including the financial statements) and any of the exhibits referred to above will be furnished at no cost to our stockholders who make a written request to our Corporate Secretary at Cocrystal Pharma, Inc., 4400 Biscayne Blvd, Suite 101, Miami, FL 33137.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.